SCHEDULE 13G/A: Lance Friedman Discloses 9.462% Passive Stake in Aspire Biopharma Holdings

Lance Friedman has disclosed a 9.462% passive beneficial ownership stake in Aspire Biopharma Holdings, Inc., totaling 4,609,375 shares of common stock.

Summary

• Lance Friedman, a U.S. citizen, has filed an Amendment No. 2 to Schedule 13G, disclosing beneficial ownership in Aspire Biopharma Holdings, Inc.
• The filing indicates that Mr. Friedman beneficially owns 4,609,375 shares of Aspire Biopharma Holdings, Inc. Common Stock.
• This ownership represents 9.462% of the company's outstanding Common Stock.
• Mr. Friedman holds sole voting power and sole dispositive power over all 4,609,375 shares.
• The shares include 1,680,886 shares held by Blackstone Capital Advisors, Inc., 2,265,989 shares held by Cobra Alternative Strategies LLC, and 662,500 shares held by Thor Special Situations LLC.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive ownership stake and does not provide specific industry context or trends.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial ownership stake by Lance Friedman provides transparency regarding the company's ownership structure, which can be of interest to existing and potential investors.

Key Dates

Keywords

Aspire Biopharma Holdings, Lance Friedman, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Blackstone Capital Advisors, Cobra Alternative Strategies, Thor Special Situations